UW Alzheimer's tau tracer wins FDA approval after 2,200 scans
A brain imaging agent that University of Wisconsin researchers helped pioneer has won FDA approval, turning years of lab work into a clinical tool for Alzheimer's diagnosis. The tracer, MK-6240, now marketed as TAUKLARIFY, lights up tau tangles in living brains. UW generated more data on it than almost any other site in the world.
- Original source: wisbusiness.com.
- The source published it on Nov 20, 2026 at 1:40 AM.
- No second outlet has reported it yet. Treat it as a single-source claim.
The U.S. Food and Drug Administration has approved MK-6240, a brain imaging agent now sold as TAUKLARIFY, moving a tool Wisconsin researchers have used for years from the lab into doctors' hands. UW Health researchers were among the earliest adopters of the tracer, which makes tau protein buildup visible in a living patient's brain. Data from their studies supplied critical evidence for the approval, according to wisbusiness.com.
Alzheimer's once could only be confirmed after death, when an autopsy revealed malformed clumps of beta amyloid and tau. Researchers spent two decades chasing imaging that works on living patients, starting with a PET tracer for amyloid plaque 20 years ago and a tau tracer about a decade later. Dr. Nate Chin, medical director of the Wisconsin Alzheimer's Disease Research Center, said the combined imaging lets doctors see what's happening in the brain while the disease unfolds and make more informed treatment decisions.
Getting there took a small army. The Wisconsin Alzheimer's Disease Research Center, the Cyclotron Research Group in the Department of Medical Physics and the Brain Imaging Core at the Waisman Center all pitched in. The tracer carries a radioactive isotope that decays fast, so the medical school's cyclotron and nuclear physics know-how were essential to producing it on demand, often daily. Sterling Johnson, associate director of the research center, said few institutions have the infrastructure to make a tracer like this routinely, crediting the cross-campus partnership for studies that otherwise wouldn't have happened. NIH funding starting in 2017 kept the work going.
Tobey Betthauser and Bradley Christian led one of the first U.S. teams to test MK-6240 on research volunteers, with a 2018 study among the first to show it could accurately image tau pathology. A 2020 study in the journal Brain, run on 167 volunteers in the long-running Wisconsin Registry for Alzheimer's Prevention, linked rising tau and amyloid levels to declining thinking, learning and memory. To date, UW researchers have run more than 2,200 scans with the tracer across 800 to 900 volunteers and patients.
The next act is treatment. Anti-tau drugs are in development, and researchers are using tau PET imaging in clinical trials to figure out which patients might benefit and whether experimental therapies hit their target, Betthauser said. No commercial launch timeline has been announced by the companies bringing MK-6240 to market. UW Health is getting ready anyway, building a clinical tau PET program with input from geriatrics, neurology and radiology, including specialists trained to read the scans. Dr. Robert Przybelski, director of UW Health Geriatric Memory Clinics, said the teams will be positioned to fold the technology into memory clinics once it's commercially available.
TopicsMK-6240 · TAUKLARIFY · University of Wisconsin School of Medicine and Public Health · UW Health · FDA · Nate Chin · Sterling Johnson · Tobey Betthauser
Source: wisbusiness.com
Written by AI from verified reporting.
More stories
- Health & science phys.org Caught by @boxlink 1 viewYale team catches excitons acting like light in a one-atom-thick material
- Health & science hoodline.com 1 viewShionogi Snags Biotech Startup in Massive $2 Billion Rare Disease Power Play
- Health & science finance.yahoo.com 1 viewMedtronic's Hugo robot clears FDA for general surgery
- Health & science wired.com 1 viewEl Niño Pushes California's Coastal Waters Off the Charts, and the Storms Are Following

